Program
disitamab vedotin
Also written as “RC48-ADC”, “Disitamab Vedotin” and “Disitamab Vedotin Injection”.
In Pfizer’s pipeline, HER2-directed antibody-drug conjugate
. Its studies are mostly in Stomach Neoplasms · Breast Neoplasms · Carcinoma, Transitional Cell · Carcinoma, Non-Small-Cell Lung · Non-Muscle Invasive Bladder Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| RemeGen | 3022 open or running | phase 3since Apr 8, 2018 | Aug 20, 2016 | Dec 2026phase 3 · NCT06221748 |
| Pfizerits history only | 55 open or running | phase 3since Jun 9, 2023 | Apr 19, 2021 | Dec 11, 2026phase 2 · NCT04879329 |
| Jiangsu HengRui Medicineits history only | 11 open or running | phase 2since Apr 26, 2024 | Apr 26, 2024 | Dec 31, 2031phase 2 · NCT06417554 |
- Named in Pfizer’s own pipeline as
disitamab vedotin PF-08046051
, phase 3, as of Nov 3, 2026 (source).
Also a collaborator on its studies: Merck.
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseSeagen licensed it from RemeGen, for everywhere outside Asia, and in Japan and Singapore.Announced Aug 9, 2021 · Source: Seagen and RemeGen (release), Aug 9, 2021
- AcquisitionPfizer acquired Seagen, and with it the rights Seagen held.Completed Dec 14, 2023 · Source: Pfizer (release), Dec 14, 2023
How Jiangsu HengRui Medicine relates to it is not in the registry or these sources.
History and studies of RemeGen only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 14 earlier studies, Aug 20, 2016 to Nov 15, 2021.
- Dec 9, 2018Named disitamab vedotinINNProposed as its International Nonproprietary Name in WHO's List 120
- Aug 9, 2021Seagen licensed it from RemeGenLicenseEverywhere outside Asia, and in Japan and Singapore · announced · Seagen and RemeGen (release)
- Mar 17, 2022Phase 2 study in Muscle Invasive Bladder CarcinomaNCT05297552 · 40 planned · China
- Mar 21, 2022Phase 3 study in Carcinoma, Transitional CellNCT05302284 · 452 planned · China
- Feb 16, 2023Phase 2 study in Carcinoma, Non-Small-Cell LungNCT05745740 · 26 planned · China
- Mar 13, 2023Phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT05943379 · 85 planned · China
- May 8, 2023Phase 1 study in Solid TumorNCT05940896 · 24 planned · China
- Jul 1, 2023Phase 3 study in Stomach NeoplasmsNCT05980481 · 201 enrolled · China
- Aug 18, 2023Phase 2 study in Solid TumorNCT06016062 · 221 planned · China
- Nov 23, 20232 phase 2 studiesNCT06155396, NCT06155383
- Dec 3, 2023Phase 2 study in Breast NeoplasmsNCT06178159 · 40 planned · China
- Dec 14, 2023Pfizer acquired SeagenAcquisitionWith it the rights Seagen held · completed · Pfizer (release)
- Jan 15, 2024Phase 3 study in Stomach NeoplasmsNCT06221748 · 90 planned · China
- Jan 17, 20242 phase 2 studiesNCT06227156, NCT06227117
- Apr 12, 2024Phase 2 study in High-risk Non-muscle Invasive Bladder CancerNCT06378242 · 24 planned · China
- Apr 17, 2025Phase 3 study in Stomach NeoplasmsNCT06944496 · 616 planned · China
- Dec 3, 2025Phase 3 study in Stomach NeoplasmsNCT07315750 · 555 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Stomach NeoplasmsNCT06221748
- Dec 31, 2026Primary completion: phase 3 study in Carcinoma, Transitional CellNCT05302284
- Jun 30, 2027Primary completion: phase 2 study in Uterine Cervical NeoplasmsNCT06155396
- Dec 1, 2027Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT05745740
TargetBeta
“HER2-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of disitamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) conjugated, via the protease-cleavable linker maleimidocaproyl-valine-…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of disitamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| zongertinibrule | Boehringer Ingelheim | phase 3 | 15 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 30 RemeGen leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07315750Stomach Neoplasms · China | 3 | Recruiting | Jun 30, 2029 | 555 |
| NCT06944496Stomach Neoplasms · China | 3 | Not yet recruiting | May 15, 2028 | 616 |
| NCT06378242High-risk Non-muscle Invasive Bladder Cancer · China | 2 | Recruiting | Mar 15, 2029 | 24 |
| NCT06227156Castration-resistant Prostate Cancer · China | 2 | Recruiting | Dec 2025 | 40 |
| NCT06227117Breast Neoplasms · China | 2 | Recruiting | Dec 2025 | 120 |
| NCT06221748Stomach Neoplasms · China | 3 | Recruiting | Dec 2026 | 90 |
| NCT06178159Breast Neoplasms · China | 2 | Recruiting | Jun 2026 | 40 |
| NCT06155396Uterine Cervical Neoplasms · China | 2 | Recruiting | Jun 30, 2027 | 116 |
| NCT06155383Stomach Neoplasms · China | 2 | Recruiting | Jan 31, 2025 | 90 |
| NCT06016062Solid Tumor · China | 2 | Recruiting | Dec 31, 2025 | 221 |
| NCT05980481Stomach Neoplasms · China | 3 | Active, not recruiting | Jul 10, 2025 | 201 |
| NCT05940896Solid Tumor · China | 1 | Recruiting | Nov 16, 2024 | 24 |
| NCT05943379Non-Muscle Invasive Bladder Neoplasms · China | 2 | Recruiting | Dec 1, 2025 | 85 |
| NCT05745740Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | Dec 1, 2027 | 26 |
| NCT05302284Carcinoma, Transitional Cell · China | 3 | Recruiting | Dec 31, 2026 | 452 |
| NCT05297552Muscle Invasive Bladder Carcinoma · China | 2 | Recruiting | Jun 1, 2024 | 40 |
| NCT05135715Melanoma · China | 2 | Recruiting | Dec 30, 2024 | 50 |
| NCT04965519Gynecological Malignancy · China | 2 | Recruiting | Oct 2024 | 120 |
| NCT04714190Stomach Neoplasms · China | 3 | Recruiting | Dec 1, 2024 | 351 |
| NCT04400695Breast Neoplasms · China | 3 | Recruiting | Dec 31, 2027 | 366 |
| NCT04329429Biliary Tract Neoplasms · China | 2 | Active, not recruiting | Nov 3, 2023 | 57 |
| NCT04311034Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Dec 21, 2021 | 37 |
| NCT04073602Carcinoma, Transitional Cell · China | 2 | Completed | Sep 30, 2022 | 19 |
| NCT03809013Carcinoma, Transitional Cell · China | 2 | Completed | Mar 4, 2021 | 64 |
| NCT03556345Stomach Neoplasms · China | 2 | Completed | Jun 1, 2020 | 127 |
| NCT03507166Carcinoma, Transitional Cell · China | 2 | Completed | Oct 29, 2018 | 43 |
| NCT03500380Breast Neoplasms · China | 3 | Active, not recruiting | Jul 31, 2024 | 301 |
| NCT03052634Advanced Breast Cancer · China | 2 | Completed | Jul 31, 2022 | 112 |
| NCT02881190Solid Tumors · China | 1 | Completed | Jun 27, 2019 | 57 |
| NCT02881138Solid Tumors · China | 1 | Completed | Apr 30, 2020 | 24 |
How it is read
Names in the registry
- “RC48-ADC”, 15 entries
- “disitamab vedotin”, 4 entries
- “Disitamab Vedotin”, 3 entries
- “Disitamab Vedotin Injection”, 3 entries
- “Disitamab vedotin”, 2 entries
Conditions, from the studies’ own filings
- Stomach Neoplasms, 7 studies
- Breast Neoplasms, 6 studies
- Carcinoma, Transitional Cell, 6 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Non-Muscle Invasive Bladder Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.